Advertisement

Topics

Clinical Trials About "FS-Elliott" RSS

20:08 EDT 20th March 2019 | BioPortfolio

We list hundreds of Clinical Trials about "FS-Elliott" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "FS-Elliott" on BioPortfolio

We have published hundreds of FS-Elliott news stories on BioPortfolio along with dozens of FS-Elliott Clinical Trials and PubMed Articles about FS-Elliott for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of FS-Elliott Companies in our database. You can also find out about relevant FS-Elliott Drugs and Medications on this site too.

Showing "Elliott" Clinical Trials, all 3

Relevant

Brain Development Research Program

Dr. Elliott Sherr and his collaborators at University of California, San Francisco (UCSF) are studying the genetic causes of disorders of cognition and epilepsy, in particular disorders of brain development that affect the corpus callosum, such as Aicardi syndrome, as well as two additional brain malformations, polymicrogyria and Dandy-Walker malformation. The goal of the investigators' research is to use a better understanding of the underlying genetic causes as a foundation t...


A Two-arm Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

A multi-center, placebo controlled, double-blind trial comparing the efficacy and safety of 18 months of treatment with deferiprone versus placebo in patients with PKAN. This investigator-initiated trial is funded by the European Commission's Seventh Framework Programme (FP7/2007-2013, HEALTH-F2-2011, grant agreement No. 277984) to the TIRCON consortium (Treat Iron-Related Childhood-Onset Neurodegeneration) and by the FDA OOPD (Dr. Elliott Vichinsky)

Possibly Relevant

Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery

The incidence of oesophagogastric cancer has increased by 400% since the 1970s in Ireland and the United Kingdom. In addition, refinement of perioperative management and the now widespread use of multimodal protocols for patients with locally advanced disease have significantly improved outcomes for patients with oesophagogastric cancer treatable with curative intent. Despite significant advances in chemoradiotherapy, surgical resection remains the primary curative option. ...



More From BioPortfolio on "FS-Elliott"

Advertisement
Quick Search
Advertisement
Advertisement